Cocrystal Pharma to Present Phase 1 Norovirus Antiviral Data at ICAR 2026

summarizeSummary

Cocrystal Pharma announced that its oral norovirus protease inhibitor, CDI-988, will be featured at the International Society for Antiviral Research Conference (ICAR) 2026, where it will present Phase 1 data and updates from an ongoing Phase 1b study.

check_boxKey Events

• CDI-988 Featured at ICAR 2026

  Cocrystal Pharma's first oral norovirus protease inhibitor, CDI-988, will be presented at the International Society for Antiviral Research Conference (ICAR) 2026, held from April 27 to May 1 in Prague, Czech Republic.

• Phase 1 Data and Phase 1b Study Updates

  The company will present initial Phase 1 data and updates from its ongoing Phase 1b norovirus challenge study, evaluating CDI-988 as both a prophylactic and therapeutic option.

• First Oral Antiviral for Norovirus

  CDI-988 is highlighted as the first oral antiviral drug candidate under development for the prevention and treatment of acute norovirus gastroenteritis, addressing a significant unmet medical need.

• Pan-Viral Protease Inhibitor Potential

  Designed using a proprietary structure-based drug discovery platform, CDI-988 targets 3CL viral proteases, indicating potential broad-spectrum antiviral activity against both noroviruses and coronaviruses.

auto_awesomeAnalysis

This 8-K announces that Cocrystal Pharma's lead oral norovirus protease inhibitor, CDI-988, will be featured at a major international antiviral research conference. The presentation will include Phase 1 data and updates from an ongoing Phase 1b challenge study. For a clinical-stage biotechnology company, presenting progress on a first-in-class drug candidate for a disease with no approved therapies or vaccines, like norovirus, is a significant positive development. This increases visibility for the program and highlights the potential of CDI-988, which also has pan-viral protease inhibitor activity against coronaviruses.